POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib
- DOI
- 10.1080/14796694.2026.2638989
- Published
- 2026-03-07
- Container
- Future Oncology
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2026.2638989,
title = {POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib},
author = {Pankit Vachhani and Abdulraheem Yacoub and Raajit Rampal and Terrence Bradley and Claire Harrison and Tania Jain and Andrew Kuykendall and Francesca Palandri and John Mascarenhas and Haifa Al-Ali and Francesco Passamonti and Wayne Rothbaum and Srdan Verstovsek and Florian H. Heidel},
year = {2026},
journal = {Future Oncology},
doi = {10.1080/14796694.2026.2638989},
url = {https://doi.org/10.1080/14796694.2026.2638989}
}RIS
TY - JOUR TI - POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib AU - Pankit Vachhani AU - Abdulraheem Yacoub AU - Raajit Rampal AU - Terrence Bradley AU - Claire Harrison AU - Tania Jain AU - Andrew Kuykendall AU - Francesca Palandri AU - John Mascarenhas AU - Haifa Al-Ali AU - Francesco Passamonti AU - Wayne Rothbaum AU - Srdan Verstovsek AU - Florian H. Heidel PY - 2026 JO - Future Oncology DO - 10.1080/14796694.2026.2638989 UR - https://doi.org/10.1080/14796694.2026.2638989 ER -
APA
Vachhani, P., Yacoub, A., Rampal, R., Bradley, T., Harrison, C., Jain, T., Kuykendall, A., Palandri, F., Mascarenhas, J., Al-Ali, H., Passamonti, F., Rothbaum, W., Verstovsek, S., & Heidel, F. H. (2026). POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib. Future Oncology. https://doi.org/10.1080/14796694.2026.2638989
Source records
- crossref · retrieved 2026-11-11T03:31:10.833Z